From "COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2" (International Journal of Vaccine Theory, Practice, and Research):
"The mainstream narrative about COVID-19 “vaccine” effectiveness in 2021 and 2022 has, it seems, boasted of non-existent benefits while greatly underestimating very real, empirically verified, cardiovascular, neurological, hematologic, and immunologic harms associated with these synthetic, modified mRNA products. Since early 2021, excess deaths, cardiac events (notably myocarditis and myocardial infarction), strokes, and other serious adverse events have often been wrongly ascribed to COVID-19 infections rather than to the COVID-19 modmRNA products." (https://ijvtpr.com/index.php/IJVTPR/article/view/104/371)

From "Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome" ("Vaccine" Journal):
"Patients with prior SARS CoV-2 infection who had detectable antibodies and received one or more doses of vaccine had significantly higher S-specific IgG levels and were more likely to develop severe heart failure or cardiogenic shock after STEMI. This association was independent of age and was even more pronounced in younger patients in a subgroup analysis. (https://www.sciencedirect.com/science/article/pii/S0264410X24009873?via%3Dihub#s0030)

From "Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects" (The American Journal of Cardiology):
"the age-adjusted incidence rate of myopericarditis in men was higher in the vaccinated group than in the control group (https://www.ajconline.org/article/S0002-9149(21)01047-X/fulltext)

From "BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis" (European Journal of Clinical Investigation):
Post-vaccination CAE rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence. (https://onlinelibrary.wiley.com/doi/10.1111/eci.13759)